# High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration

> **NCT00034242** · PHASE2 · COMPLETED · sponsor: **National Institute of Neurological Disorders and Stroke (NINDS)** · enrollment: 20 (—)

## Conditions studied

- Spinocerebellar Degenerations

## Interventions

- **DRUG:** high-dose intravenous immunoglobulin (IVIG)

## Key facts

- **NCT ID:** NCT00034242
- **Lead sponsor:** National Institute of Neurological Disorders and Stroke (NINDS)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-04
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 20 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034242, "High-Dose Intravenous Immunoglobulin to Treat Cerebellar Degeneration". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT00034242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*